Search Results

Dynavax Technologies announced Tuesday that the FDA issued a Complete Response Letter to the company’s sBLA to include a four-dose regimen of Heplisav-B vaccine for adult hemodialysis patients.

Dynavax Technologies Corporation, a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, announced that the Company will present at the following upcoming investor conferences during the month of June.

Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that the first participant has been dosed in a Phase 1/2 clinical trial evaluating the safety, tolerability, and immunogenicity of Z-1018, the company’s investigational vaccine candidate being developed for the prevention of shingles (herpes zoster), a debilitating disease caused by the varicella-zoster virus.

Dynavax Technologies Corporation, a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, reported financial results and provided a business update for the quarter ended March 31, 2024.

Dynavax Technologies Corporation provided a regulatory update for the Company’s supplemental Biologics License Application to include a four-dose HEPLISAV-B® vaccine [Hepatitis B Vaccine, Adjuvanted] regimen for adults on hemodialysis.

Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the U.S. financial markets close.